Acute myeloid leukaemia triggering via CD40 induces leukocyte chemoattraction and cytotoxicity against allogenic or autologous leukemic targets

被引:11
作者
Costello, RT
Mallet, F
Chambost, H
Sainty, D
Arnoulet, C
Gastaut, JA
Olive, D
机构
[1] Univ Mediterranee, Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France
[2] Univ Mediterranee, Inst J Paoli I Calmettes, Unite Immunol Tumeurs, F-13009 Marseille, France
[3] Univ Mediterranee, Hop Enfants La Timone, F-13009 Marseille, France
[4] INSERM, U119, Marseille, France
关键词
acute myeloid leukemia; CD40; chemokines; IL-12; immunotherapy;
D O I
10.1038/sj.leu.2401628
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The CD40 antigen is a member of the tumor necrosis factor receptor superfamily which interacts with its ligand and regulates the immune response via a dialogue between T-lymphocytes and antigen-presenting or tumor cells. Tumor triggering via CD40 exerts direct effects on cancer cells, which have mainly been investigated in terminally differentiated hematological malignancies such as low-grade lymphoma. We focused our attention on minimally differentiated acute myeloid leukemia (AML-M0), an aggressive hematological malignancy in which severe prognosis suggests the requirement for innovative therapeutic strategies. Here we demonstrate, for the first time to our knowledge, a CD40-triggered IL-8, RANTES and IL-12 secretion by leukemic cells. Supernatants from CD40-stimulated leukemia cells had chemoattractant effects on T-lymphocytes, natural killer cells and monocytes, Moreover, these supernatants, when complemented with low-dose IL-2, induced significant lymphokine-activated and natural killer cytotoxicity, leading to leukemia lysis both in allogenic HLA-matched and autologous settings. Stimulation of leukemia cells via CD40 could participate significantly to the anti-leukemia immune response by contributing to the development of an inflammatory response and to in situ cytotoxicity.
引用
收藏
页码:123 / 128
页数:6
相关论文
共 53 条
[1]   Minimally differentiated acute myeloid leukemia (AML-MO): A distinct clinico-biologic entity with poor prognosis [J].
Amadori, S ;
Venditti, A ;
DelPoeta, G ;
Stasi, R ;
Buccisano, F ;
Bruno, A ;
Tamburini, A ;
Cox, MC ;
Maffei, L ;
Aronica, G ;
Simone, MD ;
Adorno, G ;
Masi, M ;
Tribalto, M ;
Papa, G .
ANNALS OF HEMATOLOGY, 1996, 72 (04) :208-215
[2]   PROPOSAL FOR THE RECOGNITION OF MINIMALLY DIFFERENTIATED ACUTE MYELOID-LEUKEMIA (AML-MO) [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 78 (03) :325-329
[3]   PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) :620-625
[4]   MINIMALLY DIFFERENTIATED ACUTE-LEUKEMIA [J].
CADWELL, FJ ;
BURNS, CP ;
DICK, FR ;
JONES, MP ;
HECKMAN, KD ;
WEINER, GJ ;
GOEKEN, JA .
LEUKEMIA RESEARCH, 1993, 17 (03) :199-208
[5]   Tumor cells transfected with B7-1 and interleukin-12 cDNA induce protective immunity [J].
Chen, PW ;
Geer, DC ;
Podack, ER ;
Ksander, BR .
INERLEUKIN 12: CELLULAR AND MOLECULAR IMMUNOLOGY OF AN IMPORTANT REGULATORY CYTOKINE, 1996, 795 :325-327
[6]  
Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO
[7]  
2-5
[8]   THE CD2 AND CD28 ADHESION MOLECULES INDUCE LONG-TERM AUTOCRINE PROLIFERATION OF CD4+ T-CELLS [J].
COSTELLO, R ;
CERDAN, C ;
PAVON, C ;
BRAILLY, H ;
HURPIN, C ;
MAWAS, C ;
OLIVE, D .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (03) :608-613
[9]  
COSTELLO R, 1999, IN PRESS LEUKEMIA
[10]  
Costello RT, 1998, EUR J IMMUNOL, V28, P90, DOI 10.1002/(SICI)1521-4141(199801)28:01<90::AID-IMMU90>3.0.CO